Elite in Transient Ischemic Attack (TIA)

Yilong N. Wang

No 119 South 4th Ring West Road, 
Fengtai, CN 
Elite in Transient Ischemic Attack (TIA)
No 119 South 4th Ring West Road, 
Fengtai, CN 
OverviewLocationsClinical Research

Overview

Yilong Wang practices in Fengtai, China. Wang is rated as an Elite expert by MediFind in the treatment of Transient Ischemic Attack (TIA). Their top areas of expertise are Transient Ischemic Attack (TIA), Stroke, Atherosclerosis, Stent Placement, and Thrombectomy.

Their clinical research consists of co-authoring 678 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 171 articles in the study of Transient Ischemic Attack (TIA).

Locations

No 119 South 4th Ring West Road, Fengtai, 100070, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Clinical Study to Evaluate the Safety and Efficacy of Intracranial Balloon Angioplasty Plus Aggressive Medical Management for Symptomatic Intracranial Artery Stenosis
A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Clinical Study to Evaluate the Safety and Efficacy of Intracranial Balloon Angioplasty Plus Aggressive Medical Management for Symptomatic Intracranial Artery Stenosis
Enrollment Status: Unknown
Publish Date: July 03, 2023
Intervention Type: Drug, Device
Study Phase: Not Applicable
PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)
PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)
Enrollment Status: Unknown
Publish Date: March 19, 2020
View 1 Less Clinical Trial

678 Total Publications

CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke.
CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke.
Journal: Stroke
Published: September 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 41 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile